Call us today 212-583-0100

ENZO Biochem Appoints Carl W. Balezentis, Ph.D., President Of Enzo Life Sciences Subsidiary

FARMINGDALE, NY, June 8, 2006 – Enzo Biochem, Inc. (NYSE:ENZ) today announced the appointment of Carl W. Balezentis, Ph.D. to the newly created position of President of Enzo Life Sciences, Inc.  Dr. Balezentis, a senior executive with 18 years experience in the life sciences industry, was CEO of Lark Technologies, Inc., prior to its acquisition by Genaissance Pharmaceuticals, Inc.
 
Enzo Life Sciences, a wholly owned subsidiary of Enzo Biochem, develops, manufactures and markets biomedical research products, nonradioactive labeling and detection protocols, as well as reagents for molecular biology research, including microarray methodologies for both gene expression and genomic analysis applications.
 
“Dr. Balezentis’ broad managerial, operational and marketing experience in life sciences makes him a valuable addition to our team,” said Barry Weiner, President of Enzo Biochem.  “He will assume responsibility for operations and implement strategies for the development and expansion of this important Enzo unit.  We anticipate that his proven capabilities in the biotechnology services area will enable Enzo Life Sciences to further capitalize on our Company’s extensive Intellectual Property.”
 
After Lark Technologies’ acquisition, Dr. Balezentis joined Genaissance (which itself was subsequently acquired), a company that develops technologies to improve drug discovery and marketing, utilizing population genomics to predict which patients will respond effectively to a drug, as Senior VP.  He was responsible for the rapid integration of Lark’s facilities in the US and UK into Genaissance, and developed sales and marketing strategies aimed at fully utilizing the resources of both companies and developing synergistic opportunities.  He spent a total of five years with both companies.
 
Previously, Dr. Balezentis was Director of Business Development of the multi-million dollar Life Sciences Division of Sigma-Aldrich Inc, where he had global responsibility for developing, organizing and leading business development activities, after previously serving as VP Sales and Marketing of Genosys Biotechnologies, Inc., which was acquired by Sigma-Aldrich.  He also served as Director of Marketing at Perceptive Scientific Instruments, Inc., acquired by International Remote Imaging Systems, and as Group Leader-Human Identity Products at Applied Biosystems, Inc. (now Applera Corporation). 
 
Among other positions he has held, Dr. Balezentis was Director – Gene Identity at Promega Corporation, Chief Scientific Officer of Molecular Identity Testing, Inc.; and Scientific/Technical Director of Molecular Diagnostic Associates, Inc.
 
Dr. Balezentis holds a BS degree in Biology and a Ph.D. in Genetics from the University of Arizona, in Tucson, and a Post Doctoral Fellowship at M.D. Anderson Cancer Center, in Houston, TX.    He was a co-founder and Board Member of the Human Identity Trade Association, in addition to chairing in 1992 and 1993 the International Symposium on Human Identity.

About Enzo
Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company's proprietary labeling and detection products for gene sequencing and genetic analysis are sold to the life sciences market throughout the world. The Company's therapeutic division is in various stages of clinical evaluation of its proprietary gene medicine for HIV-1 infection and its proprietary immune regulation medicines for hepatitis B and hepatitis C infection and for Crohn's Disease. Pre-clinical research is being conducted on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications. The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes. The Company owns or licenses over 200 patents worldwide. For more information visit our website www.enzo.com.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.